

Europe



Autogenous Vaccines and Their Role in Animal Health Strategy

September 25-26, 2017

Het Pand

University of Ghent

Co-organized by IABS-EU and University of Ghent / PROVAXS

The purpose of this conference is to start from an overview on the current situation and needs from the perspective of regulators, scientists, manufacturers and the end-user (veterinarians). The main focus will be on food producing animals, including fish. Further, proposals will be presented for a harmonized approach which will lead to a better understanding of the rationale for the intended use, better knowledge on the nature of isolates and improved production and quality of the final products. In addition, advanced techniques and methods will be presented and discussed to identify and propagate isolates, to upgrade production and to quickly estimate safety and even efficacy of autogenous vaccines by *in vitro* methods.

Recommendations will be drafted on how to improve the EU-legislation and communication between the EU-Member States on autogenous vaccines and on ways to increase transparency on quality and safety of the vaccines.

Scientific / Organizing Committee

Carmen	Jungbäck	IABS-EU
Joris	Vandeputte	IABS
Sven	Arnouts	University of Ghent – PROVAXS, Belgium
Eric	Cox	University of Ghent – PROVAXS, Belgium
Vilma	Dosedlová	Institute for State Control of Veterinary Biologicals and Medicines, Czech Republic
Sjaak	de Wit	Deventer, The Netherlands
Jacques	Léchenet	Boehringer-Ingelheim
Peter	Schmid	IDT Biologika, Germany

Day 1 – Afternoon Monday, September 25, 2017

- 12:30-13:00 Registration
- 13:00-13:15 Opening
Prof. Frank Gasthuys (Dean of the Faculty of Veterinary Medicine, University of Ghent)

Session 1 The role of autogenous vaccines

Chairpersons:

Dr. Vilma Dosedlova, Institute for State Control of Veterinary Biologicals and Medicines, Czech Republic

Dr. Peter Schmid, IDT Biologika, Germany

- 13:15-13:30 Differences to minor markets/minor use (MUMS), emergency licensing, regular licensing
Dr. Carmen Jungbäck, IABS-EU
- 13:30-13:45 When can autogenous vaccines replace or complement licensed vaccines: view of a manufacturer of autogenous and licensed vaccines
Dr. Peter Schmid, IDT Biologika, Germany
- 13:45-14:00 Production and use of autogenous vaccines for pigs in Germany
Dr. Adrian Luehrs, Vaxxinova, Germany
- 14:00-14:15 Practices and relevance for use of autogenous vaccines. Are “non-registered vaccines” proper alternatives?
Dr. Hans-Jørgen Riising, National Veterinary Institute, Technical University of Denmark
- 14:15-14:45 Discussion
- 15:00-15:30 Coffee break

Session 2 Current legal basis and proposals for update: regulators

Chairpersons:

Dr. Carmen Jungbäck, IABS

Dr. Sjaak de Wit, Deventer, The Netherlands

- 15:30-15:45 Situation in Belgium
Dr. Dries Minne, Federal Agency for Medicines and Health Products (FAMHP), Belgium
- 15:45-16:00 Current situation on veterinary autogenous vaccines in the Czech Republic
Dr. Vilma Dosedlova, Institute for State Control of Veterinary Biologicals and Medicines, Czech Republic
- 16:00-16:15 Situation in the United Kingdom
Dr. Noemi del Blanco, Veterinary Medicines Directorate, United Kingdom
- 16:15-16:30 EU approach: CMDv/HMA
Dr. Mariette Salery, ANSES-ANMV, Immunological Assessment Unit, France
- 16:30-16:45 The legal basis for autogenous vaccine for veterinary use production and application in Ukraine
Dr. Anton Gerilovych, National Scientific Center «Institute for Experimental and Clinical Veterinary Medicine», Ukraine
- 16:45 – 17:15 Discussion

Day 2 – Morning Tuesday, September 26, 2017

Session 3

Current production: manufacturers and veterinarians, solutions for better vaccines

Chairpersons:

Dr. Sven Arnouts, University of Ghent – PROVAXS, Belgium

Dr. Eric Cox, University of Ghent – PROVAXS, Belgium

- 08:30-08:45 What are we going for, justified use of autogenous vaccines?
Dr. Sjaak de Wit, Deventer, The Netherlands
- 08:45-09:00 The production and using of autogenous vaccines (AV) in pig and cattle farming - the experiences of the producer
Dr. Ladislav Pazout, Dyntech, Czech Republic
- 09:00-09:15 Autogenous vaccines: targets, volumes and production requirements
Dr. Peter Behr, Anicon
- 09:15-09:30 Autogenous and Commercial Vaccines: the standpoint of a company dealing with both products
Dr Jean de Foucauld, Ceva Santé Animale, France
- 09:30-09:45 The role and importance of autogenous vaccines
Dr. Jean-Pascal Marc, Virbac, France
- 09:45-10:00 The view of Boehringer Ingelheim on autogenous vaccines in EU
Dr. Jacques Léchenet, Boehringer-Ingelheim, France
- 10:00-10:30 Coffee break
- 10:30-10:45 The use of autogenous vaccines in the current veterinary practice
Dr. Frans Dirven, Lintjeshof, The Netherlands
- 10:45-11:00 Use of autogenous vaccines in poultry – holy grail or much ado about nothing?
Dr. Maarten De Gussem, Poulpharm, Belgium
- 11:00-11:15 Autogenous vaccines, an Atlantic salmon farming perspective
Dr. Dave Cockerill, Marine Harvest, Scotland
- 11:15-11:45 Discussion
- 11:45-12:00 Novel technologies path the way for safe and efficacious inactivated vaccines for booster vaccinations in sows against porcine reproductive and respiratory syndrome
Dr. Hans Nauwynck, University of Ghent-PROVAXS, Belgium
- 12:00-12:15 Comparison of Adjuvants for Stimulation of HI Antibody Responses to IAV-S and Challenge Protection against FMD
Dr. Ernest Kontor, Phibro Animal Health Corporation, U.S.A.
- 12:15-12:30 Manufacturing process optimization of emulsified vaccines for the autogenous vaccine market
Dr. Ghislaine Ionkoff, SEPPIC, France
- 12:30-12:45 RNA particle vaccines in the US through veterinary prescription
Dr. Ruud Segers, MSD- Animal Health, The Netherlands
- 12:45-13:15 Discussion
- 13:15-14:15 Lunch

Day 2 – Afternoon Tuesday, September 26, 2017

Session 4 Updating legal basis

Chairperson:

Dr. Joris Vandeputte, President, IABS
Dr. Jacques Léchenet, Boehringer-Ingelheim, France

- 14:15 – 14:45 Summary of the sessions and the discussions
Dr. Vilma Dosedlova, Institute for State Control of Veterinary Biologicals and Medicines, Czech Republic; **Dr. Peter Schmid**, IDT Biologika, Germany; **Dr. Carmen Jungbäck**, IABS
Dr. Sjaak de Wit, Deventer, The Netherlands; **Dr. Sven Arnouts**, University of Ghent – PROVAXS, Belgium; **Dr. Eric Cox**, University of Ghent – PROVAXS, Belgium
- 14:45 – 15:00 Position of the European Parliament
Françoise Grossetête, Member of Parliament
- 15:00 – 15:15 Position of the European Commission
Sabine Jülicher, Directorate General for Health and Food Safety
- 15:15 – 15:45 Plenary / Panel discussion
All speakers and moderators
- 15:45 – 16:15 Conclusions and recommendations
- 16:15 – 16:20 Closing remarks
Organizers